US biotech Seagen (Nasdaq: SGEN) has entered into exclusive license agreement with Dutch and US firm LAVA Therapeutics (Nasdaq: LVTX) to develop and commercialize the latter’s LAVA-1223.
LAVA’s shares rocketed 135% to $2.40 in pre-market trading on the news
LAVA-1223 is an advanced pre-clinical asset that utilizes LAVA’s proprietary Gammabody technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze